Overview

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Status:
Enrolling by invitation
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study will test the effectiveness and relative efficacy of naltrexone/bupropion medication as a maintenance therapy for the treatment of binge eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst responders to acute treatments, naltrexone/bupropion medication results in superior maintenance and longer-term outcomes compared with placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Bupropion
Naltrexone